Compounds > vadimezan

Page last updated: 2024-09-03

vadimezan and zd 6126

vadimezan has been researched along with zd 6126 in 10 studies

Compound Research Comparison

Studies (vadimezan)	Trials (vadimezan)	Recent Studies (post-2010) (vadimezan)	Studies (zd 6126)	Trials (zd 6126)	Recent Studies (post-2010) (zd 6126)
272	16	101	76	2	12

Research

Studies (10)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (70.00)	29.6817
2010's	3 (30.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Horsman, MR; Siemann, DW	1
Thorpe, PE	1
Chaplin, DJ; Horsman, MR; Siemann, DW	1
Bukowski, RM; Cooney, MM; Ortiz, J; Remick, SC	1
Raben, D; Ryan, A	1
Breidahl, T; Horsman, MR; Maxwell, RJ; Nielsen, FU; Stødkilde-Jørgensen, H	1
Eskens, FA; Hinnen, P	1
Cai, YC; Xian, LJ; Zou, Y	1
Lenihan, DJ; Subbiah, IM; Tsimberidou, AM	1
de Witte, P; Lerut, E; Marysael, T; Ni, Y	1

Reviews

7 review(s) available for vadimezan and zd 6126

Article	Year
Enhancement of radiation therapy by vascular targeting agents. Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:11 Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Humans; Neovascularization, Pathologic; Organophosphorus Compounds; Xanthenes; Xanthones	2002
Vascular targeting agents as cancer therapeutics. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-15, Volume: 10, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Cell Division; Clinical Trials as Topic; Diphosphates; Genetic Therapy; Humans; Hypoxia; Immunotoxins; Ligands; Models, Biological; Necrosis; Neoplasms; Organophosphorus Compounds; Peptides; Radioimmunotherapy; Stilbenes; Time Factors; Up-Regulation; Xanthones	2004
Vascular-targeting therapies for treatment of malignant disease. Cancer, 2004, Jun-15, Volume: 100, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Combined Modality Therapy; Endothelium, Vascular; Neoplasms, Experimental; Organophosphorus Compounds; Stilbenes; Xanthones	2004
Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds. Current oncology reports, 2005, Volume: 7, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Endothelium, Vascular; Humans; Neoplasms; Organophosphorus Compounds; Stilbenes; Xanthones	2005
Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005? Clinical lung cancer, 2005, Volume: 7, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Vascular Endothelial Growth Factors; Xanthones	2005
Vascular disrupting agents in clinical development. British journal of cancer, 2007, Apr-23, Volume: 96, Issue:8 Topics: Animals; Antineoplastic Agents; Blood Vessels; Humans; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Organophosphorus Compounds; Regional Blood Flow; Stilbenes; Tubulin Modulators; Xanthones	2007
[Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents]. Yao xue xue bao = Acta pharmaceutica Sinica, 2010, Volume: 45, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Diphosphates; Endothelial Cells; Humans; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Organophosphorus Compounds; Serine; Stilbenes; Tubulin Modulators; Xanthones	2010

Other Studies

3 other study(ies) available for vadimezan and zd 6126

Article	Year
The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS. Acta oncologica (Stockholm, Sweden), 2006, Volume: 45, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Female; Hydrogen-Ion Concentration; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Animal; Mice; Mice, Inbred C3H; Nucleosides; Organophosphorus Compounds; Phosphates; Stilbenes; Time Factors; Treatment Outcome; Xanthones	2006
Cardiovascular toxicity profiles of vascular-disrupting agents. The oncologist, 2011, Volume: 16, Issue:8 Topics: Angiogenesis Inhibitors; Bibenzyls; Cardiovascular System; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Quinazolines; Serine; Xanthones	2011
Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors. Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:11 Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Mice; Mice, Inbred C3H; Necrosis; Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Perylene; Telomere-Binding Proteins; Xanthones	2011